SunHo R&D pipeline strategy reflects our long-standing commitment to establish diversified and sustainable pipeline of differentiated best-in-class and first-in-class products. Based on SunHo’s proprietary and patented Armed ImmunoCytokine Platform AIC™, Armed Innate-effector Multispecific Platform AIM™, and ADCC Enhanced Antibody Platform AEA™, we focus on immunology and tumor microenvironment, and strive to explore the frontier of innovation with global vision to meet unmet clinical needs. With in-depth understanding and experience in immunology, we are expanding our footprint in novel therapeutic areas, including autoimmune diseases, neurodegenerative disorders, and viral infection.

With profound understanding of immunology and tumor microenvironment, we strive to identify and meet the most critical clinical needs, as evidenced by our pipeline of over 20 truly globally innovative and differentiated products, of which 4 are undergoing clinical trials, including IAE0972, IAP0971, IBC0966 and IAH0968. IAE0972 and IAP0971 are the first armed EGFR/IL10 and PD1/IL15 bi-functional immunocytokines based on SunHo AIC™ platform to receive IND approval from both FDA and NMPA; IBC0966 is the first PDL1/SIRPα dual-target mAb-Trap antibody fusion protein to enter clinical trials; IAH0968 is the first fully fucose-free ADCC-enhanced HER2 antibody developed based on SunHo AEA™ platform. We are currently conducting clinical trials on both monotherapy and combo therapy, late-line and first-line therapy in multiple clinical indications. We dedicate to address major unmet medical needs, including relapse or resistance of existing drugs, low overall objective response rate, short overall survival time, high toxicity, small safety window, etc. We aspire to provide state-of-the-art therapeutic biologics for patients worldwide.

SunHo attaches great importance to protect intellectual property, safeguard innovative products, and guarantee future commercial benefits. Through comprehensive consideration of products, technologies, markets, regions, and overall strategies, SunHo forms valuable patent portfolio to protect the R&D achievements effectively. Following the progress of products, more than 60 global patents have been submitted, covering core sequences, formulation, methods, structures, core platforms, etc.